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therapyDear Editor,
Infection is a major cause of morbidity and mortality in
patients with myeloma because of dysfunction of the im-
mune system due to the disease. Many novel agents have
recently been introduced for the treatment of myeloma
with promising effects; however, the interplay of these
agents with the myeloma may increase the susceptibility
of these patients to infectious complications [1]. In this
paper, we report a patient with a rare complication of
tuberculosis meningitis during bortezomib-containing in-
duction therapy.
A 59-year-old woman was diagnosed with multiple
myeloma (l light chain, Ann-Arbor stage III) in October
2013 and received bortezomib (1.3 mg/m2 s.c.) every
week plus dexamethasone (20 mg/day) and thalidomide
(50 mg/day) every 21 days. After four courses of treat-
ment, bone marrow and serum markers follow-up tests
revealed a very good partial response. However, mild
fever and progressive paraplegia were noted in June
2014. A brain magnetic resonance imaging (MRI) study
revealed multiple microabscesses (Figures 1A and 1B). A
cerebrospinal fluid (CSF) study revealed possible tuber-
culosis meningitis (opening pressure, 400 mmH2O; white
blood cell count, 88 cells/mL; polymorphonuclear neutro-
phil/lymph, 74%/26%; glucose, 40 mg/dL; protein,
181 mg/dL). The tuberculosis (TB) polymerase chain re-
action test of the cerebrospinal fluid sample showed a
positive result. The lung field on the chest radiograph
remained clear, and sputum smears showed no acid-fast
bacilli for three sets. High-dose steroid with anti-TB
medication (rifampin, 600 mg/day; isoniazid, 400 mg/
day; pyrazinamide, 1250 mg/day; ethambutol, 800 mg/
day) were prescribed, and the symptoms improvedConflicts of interest: All authors declare no conflicts of interest.
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with previous studies, which showed all sensitive Myco-
bacterium tuberculosis 1 month later. She completed the
1-year anti-TB therapy without obvious complications.
After 1 year, a follow-up brain MRI study showed resolution
of the microabscesses (Figures 1C and 1D). The patient has
had no significant neurologic defect.
Bortezomib, a human 26S proteasome inhibitor and a
potent inhibitor of ClpP1P2 activity and bacterial growth, is
a novel agent for treating multiple myeloma. It may also be
a new agent for tuberculosis therapy because Mycobacte-
rium tuberculosis is the only known bacterial pathogen
with proteasomes [2]. Bortezomib induces apoptosis of
proliferating neoplastic cells and prevents the activation of
nuclear factor-kappa B; therefore, it may decrease CD4þ T
cells, which may worsen the immune dysfunction of
myeloma patients [3].
Patients undergoing bortezomib therapy have an
increased rate of VZV/HSV infection, but only few
cases of TB infection/reactivation have been reported
[1]. Ahn et al. [4] reported eight (7%, 8/117) patients who
experienced pulmonary tuberculosis with bortezomib-
containing chemotherapy, and demonstrated that the
infection impacted survival. However, based on six pa-
tients who had tuberculosis after treatment, Kim et al. [5]
suggested that the susceptibility to tuberculosis may
come from other combination therapies. To the best of
our knowledge through a literature review, this is the
first case report of TB meningitis during bortezomib-
containing therapy. The relationship of TB infection and
bortezomib therapy remains equivocal; however, these
data stress the importance of having a high degree of
suspicion and early detection in the diagnosis, especially
in endemic areas and occult infection sites such as the
meninges.y Elsevier Taiwan LLC. This is an open access article under the CC
).
Figure 1. (A, B) In June 2014, brain magnetic resonance imaging shows multiple microabscesses over the cerebrum and cere-
bellum. (C, D) In October 2015, a follow-up study shows near total resolution after therapy.
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